Los Angeles, California (PRWEB) January 18, 2006 -–
Lawsuits continue to be filed against Pfizer, the maker of Bextra, although Bextra was removed from U.S. and Canadian shelves months ago. Bextra, the popular treatment for arthritis, was banned after the FDA confirmed major risks of cardiovascular damage and fatal skin diseases.
Plaintiffs complain that Pfizer knew of the destructive side effects of Bextra but continued to manufacture and market the drug to secure million dollar profits. Bextra lawsuits around the country seek justice and compensation for cases of death and heart attacks. In one case, the victim was only using Bextra for nine months.
Seeking legal help, consumers submit their Bextra complaints to LawyersandSettlements.com and choose a lawyer in hopes of legal representation and compensation. Consumers taking Bextra have complained about heart attacks/strokes, stomach ulcers, deadly skin diseases Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, anaphylactic shock, and liver damage.
Medical professionals continue to complain that whole classes of pain relievers, Cox-2 inhibitor drugs and NSAIDS, are dangerous. Recently, after in-depth analysis, the FDA issued a warning label change for all Cox-2 inhibitor drugs and NSAIDS, including Bextra, Celebrex, Vioxx, Aspirin, ibuprofen, and Aleve, to note an increased risk of cardiovascular (CV) problems and potential life-threatening gastrointestinal (GI) bleeding.
LawyersandSettlements.com promotes free case evaluations for those affected by Bextra and other dangerous drugs. To join a Bextra class action lawsuit, submit your case for free legal evaluation by visiting: https://www.lawyersandsettlements.com/case/bextra
About Online Legal Marketing (OLM) and http://www.lawyersandsettlements.com:
LawyersandSettlements.com offers a comprehensive website with up-to-date legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers can receive free case evaluations. Justice for Everyone.
Visit us at:
Contact us at: